Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label, Single Institution Study to Assess the Safety, Tolerability, and Pharmacokinetics of Durvalumab in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, and Central Nervous System Tumors
Conditions
Interventions
Durvalumab; MEDI4736
Locations
1
United States
Children's Hospital Los Angeles
Los Angeles, California, United States
Start Date
July 1, 2016
Primary Completion Date
November 30, 2022
Completion Date
April 30, 2023
Last Updated
September 22, 2023
NCT06132828
NCT06144671
NCT04570423
NCT07539441
NCT07249528
NCT06926283
Lead Sponsor
Leo Mascarenhas
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions